About this trial
Alport syndrome (AS) is caused by pathogenic variants in the type IV collagen genes COL4A3, COL4A4, and COL4A5. This study aims to enroll families and patients with a history of renal hematuria in 27 hospitals and detect these three genes for AS screening. This study also aims to analysis the effect of COL4A3/COL4A4/COL4A5 genotype on the development of kidney disease.
Eligibility criteria
Qualifiers
Age: up to 99 Years (Child, Adult, Older Adult)
Sex: All;
Families and patients with a history of renal hematuria;
Those who signed the informed consent.
Disqualifiers
Polycystic kidney disease, hypertensive nephropathy, etc.;
Kidney biopsy is diagnosed as other primary/secondary kidney disease without type IV collagen-related kidney disease, including IgA nephropathy, membranous nephropathy, lupus nephritis, etc.
Incomplete medical history or clinical data.
Trial design
Treatments tested in this trial
- Not listed